The European Commission (EC) has granted marketing authorisation for Aucatzyl (obecabtagene autoleucel or ‘obe-cel’) for the treatment of adult patients, 26+, with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (r/r B-ALL). The EC approval was based on the results of the FELIX study, an open-label, multi centre, single arm study in adult patients with […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
